My OperaOSI 774
Saturday, January 8, 2011 1:32:05 PM
OSI - 774 of lung cancer and head and neck cancer application value
2 The latest phase Ⅱ clinical trial results show that, OSI Pharmaceuticals, Genentech Inc. and Roche jointly developed epidermal growth factor receptor tyrosine kinase inhibitor OSI-774 in non-small cell lung cancer and head and neck squamous cell cancer effect. 57 epidermal growth factor receptor-positive advanced non-small cell lung cancer patients participated in the first clinical trials conducted prior to these patients to platinum-based chemotherapy anti-cancer drugs fail. Patients with oral OSI-774 (Tarceva) 150mg/day, resulting in 2% of patients achieved complete response, 14% of patients received a partial response, stable disease 26% of patients for more than 3 months. The median survival was 257 days, 48% of the expected survival of patients can be more than 1 year. 2 of 124 trials and has been inoperable advanced head and neck squamous cell carcinoma patients. The results, 6% of patients received a partial response, 39% of patients had stable disease for more than 3 months, the median survival time was 74 days.
Patients for the 150mg/day dose was well tolerated, the most common side effects are reversible acne-like rash and occasional diarrhea.
2 The latest phase Ⅱ clinical trial results show that, OSI Pharmaceuticals, Genentech Inc. and Roche jointly developed epidermal growth factor receptor tyrosine kinase inhibitor OSI-774 in non-small cell lung cancer and head and neck squamous cell cancer effect. 57 epidermal growth factor receptor-positive advanced non-small cell lung cancer patients participated in the first clinical trials conducted prior to these patients to platinum-based chemotherapy anti-cancer drugs fail. Patients with oral OSI-774 (Tarceva) 150mg/day, resulting in 2% of patients achieved complete response, 14% of patients received a partial response, stable disease 26% of patients for more than 3 months. The median survival was 257 days, 48% of the expected survival of patients can be more than 1 year. 2 of 124 trials and has been inoperable advanced head and neck squamous cell carcinoma patients. The results, 6% of patients received a partial response, 39% of patients had stable disease for more than 3 months, the median survival time was 74 days.
Patients for the 150mg/day dose was well tolerated, the most common side effects are reversible acne-like rash and occasional diarrhea.
